Suggested remit: To appraise the clinical and cost effectiveness of vosoritide within its marketing authorisation for treating achondroplasia in people 4 months and over.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6488

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6488 14 March 2025 - 11 April 2025

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
14 March 2025 In progress. Scoping commenced.
12 December 2024 Referral
30 October 2024 Please note that ID3807 and ID6488 have now been combined into one appraisal. The ID number will remain as ID6488.
21 March 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual